Cancer immunotherapy has set new standards in cancer care, but many patients are still not responding. RNA modifying enzymes (RME) research could be a way to improve results. DDW’s Megan Thomas reflects on STORM Therapeutics’ approach for the future of this mechanism of action.   Turning points and catalysts March 2011 was a turning point in […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!